Our results indicate that further investigation to determine if mutations affecting MLL3/4 COMPASS can predict a higher sensitivity or response to these nucleotide synthesis inhibitors will be critical for personalizing and enhancing patient treatments for cancers and developmental diseases. This evidence concerns the gene KMT2C and cancer.